INmune Bio Submits Final Pre-Marketing Authorization Application Package To UK MHRA For Ebstrocel For Recessive Dystrophic Epidermolysis Bullosa; Expects Full MAA Submission In Early February 2027, With Potential UK Approval In Mid-2027; Has Engaged U.S. Regulatory Advisors With Rare Disease Expertise To Prepare And Submit A Type B Meeting Request To FDA
INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application
Share
Why It Matters
INmune Bio is moving forward with approval steps in the UK and US. This shows the company is progressing on a medicine for a rare skin disease.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.